ArticleTranslational cancer research2025
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters combined with serum apolipoprotein A1 in patients with diffuse large B-cell lymphoma: a clinical study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive tumor. This study aims to assess the value of metabolic parameters from 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( Methods: A total of 138 newly diagnosed DLBCL patients were consecutively enrolled at our institution from January 1, 2015, to December 31, 2019. All patients underwent Results: The ApoA1 levels were 0.94 [interquartile range (IQR), 0.89, 1.05], ranging from 0.58 to 1.26; tMTV levels were 343 (IQR, 306, 360) mL, ranging from 255 to 416; and SUVmax levels were 18.6 (15.6, 21.8), ranging from 8.7 to 29.3. Analysis based on median ApoA1, tMTV, and SUVmax levels showed that compared with the high ApoA1, low tMTV, and low SUVmax group, the PFS was significantly reduced in the low ApoA1, high tMTV, and high SUVmax group. After adjusting for National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and pathological diagnosis, ApoA1, SUVmax, and tMTV remained independent factors affecting PFS. Conclusions: In DLBCL patients, high levels of metabolic parameters from 18F-FDG PET/CT (SUVmax and MTV) and low levels of serum ApoA1 indicate a poorer survival outcome, suggesting that these parameters could serve as potential biomarkers for treatment response and survival results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.